πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

227 results for β€œShi” Clear

  1. HEC121120 tablets

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  2. HEC169096

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  3. HEC585

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    5 trials

  4. HEC585 dose A

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)

    phase 2 small molecule active

    1 trial

  5. HEC96719

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  6. Injection of humanized nerve growth factor (NGF) antibody

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Cancer Pain

    phase 2 small molecule active

    1 trial

  7. Isturisa 1 mg film-coated tablets, Isturisa 5 mg film-coated tablets, Isturisa 10 mg film-coated tablets

    Recordati Ireland

    Cushing's disease

    phase 2 small molecule active

    1 trial

  8. KN046 （PD-L1/CTLA4 BsAbοΌ‰

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced HCC

    phase 2 small molecule terminated

    1 trial

  9. Osilodrostat

    Novartis Pharmaceuticals

    Cushing's Syndrome

    phase 2 small molecule completed

    1 trial

  10. Pre-operative chemotherapy

    Nanjing Zenshine Pharmaceuticals

    Gastric Cancers

    phase 2 small molecule active

    1 trial

  11. Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Psoriasis

    phase 2 small molecule active

    1 trial

  12. Recombinant Anti-IL-1Ξ² Humanized Monoclonal Antibody Injection 100 mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout Arthritis

    phase 2 small molecule active

    1 trial

  13. Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial

  14. Recombinant Human Erythropoiesis Injection (CHO cell)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Renal Failure With Hemodialysis

    phase 2 small molecule active

    1 trial

  15. Recombinant anti-PD-1 humanized monoclonal antibody injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Sarcoma, Soft Tissue

    phase 2 small molecule active

    1 trial

  16. Recombinant human arylsulfatase A

    Shire

    Metachromatic Leukodystrophy (MLD)

    phase 2 mab completed

    1 trial

  17. Rezvilutamide

    Nanjing Zenshine Pharmaceuticals

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  18. S-337395

    Shionogi B.V.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial

  19. S-606001 matching placebo, S-606001

    Shionogi B.V.

    Late-onset Pompe disease.

    phase 2 small molecule active

    1 trial

  20. SHP611

    Shire

    Metachromatic Leukodystrophy (MLD)

    phase 2 small molecule active

    1 trial

  21. SPGL008

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    NMIBC

    phase 2 mab active

    1 trial

  22. SPI-62_DF2

    Lacuna Pharma Pty Ltd

    Cushing's Syndrome

    phase 2 small molecule active

    1 trial

  23. SSGJ-705

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Locally Advanced, Recurrent or Metastatic Malignancies

    phase 2 small molecule active

    2 trials

  24. SSGJ-706

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    First-line Advanced NSCLC Patients

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources